E71.522
Adrenomyeloneuropathy
Clinical Classification Guidelines
Medical Intelligence & Overview
Adrenomyeloneuropathy (AMN) is a rare genetic disorder that affects the nervous system and adrenal glands. It is a form of adrenal leukodystrophy, impacting the spinal cord and peripheral nerves, leading to progressive neurological problems and adrenal insufficiency. This condition usually manifests in adulthood and is inherited in an X-linked pattern, predominantly affecting males. Understanding its causes, symptoms, diagnosis, and treatment options can help in managing the condition effectively.
Causes & Symptoms
Clinical Causes: Genetic mutations in the ABCD1 gene, which is responsible for producing a protein involved in breaking down very long-chain fatty acids Inheritance pattern: X-linked recessive, meaning males are more affected, while females may be carriers Accumulation of very long-chain fatty acids in nerve tissues and adrenal glands, leading to neurodegeneration and adrenal failure
Key Symptoms: Progressive weakness and stiffness in the legs Difficulty walking and loss of coordination Muscle atrophy Spasticity or increased muscle tone Sensory disturbances such as numbness or tingling Bladder and bowel dysfunction Adrenal insufficiency symptoms like fatigue, muscle weakness, weight loss, and low blood pressure Possible cognitive and behavioral changes in some cases
Diagnostic & Treatment
Diagnosis Path: Clinical evaluation of neurological and adrenal symptoms Blood tests to measure levels of very long-chain fatty acids (VLCFAs) Genetic testing for ABCD1 gene mutations Imaging studies such as MRI to detect white matter abnormalities in the brain and spinal cord Adrenal function tests to assess hormonal levels and adrenal gland activity
Treatment Protocols: There is no cure for AMN; treatment focuses on managing symptoms and preventing complications Hormone replacement therapy to address adrenal insufficiency Physical therapy and rehabilitation to improve mobility and maintain muscle strength Assistive devices, like wheelchairs or braces, may be used to enhance mobility Medications to control spasticity or pain Regular monitoring and supportive care to manage neurological symptoms and prevent secondary issues
Clinical Advice & FAQs
Billing Guidance
Is E71.522 a billable ICD-10 code?
Yes, E71.522 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E71.522?
Clinical documentation must specify the nature of Adrenomyeloneuropathy and any associated comorbidities for accurate reporting.
Cite this Clinical Reference